Daily Aspirin Linked to New Onset Heart Failure

Researchers at the University of Leuven (Belgium), Imperial College London (Imperial; United Kingdom), and other institutions conducted a meta-analysis of 30,827 patients (33.9% female, mean age 66.8 years) at risk for HF, who were enrolled in six observational studies. The study wished to evaluate the role of aspirin use on HF incidence for both primary and secondary prevention. Cardiovascular risk factors and aspirin use were recorded at baseline, and patients were followed up to the first incident of fatal or non-fatal HF.

The results showed that over 5.3 years of follow-up, 1,330 of the patients experienced HF. Overall, the incidence rate of HF per 1,000 person-years for the entire population (before adjustment) was 14.5 in the group on daily aspirin, versus 5.9 in the non-aspirin group. In the 22,690 patients without a prior history of cardiovascular disease (CVD), the HF risk increase for exposure to daily aspirin was about the same. The study was published on November 22, 2021, in ESC Heart Failure.

“These data are not relevant to primary or secondary prevention of cardiovascular events, but refer only to starting aspirin for secondary prevention in patients at high risk of heart failure, or with symptomatic heart failure,” concluded senior author Professor Emeritus Jan Staessen, MD, PhD, of the University of Leuven. “Given the consistency of these results, our observations suggest that aspirin should be prescribed with caution in patients at risk of heart failure or having heart failure.”

Aspirin's efficacy as an anticlotting agent and its widespread use as a preventive treatment for CVD and strokes have made it into one of the most widely used medications in the world. The updated guidelines (issued in March 2019) by the American College of Cardiology (ACC) and the American Heart Association (AHA) suggest that people over age 70 should avoid aspirin if they do not have overt CVD, but that it may still be considered for certain people 40-70 years of age who are at heightened risk of cardiovascular complications.

Related Links:
University of Leuven
Imperial College London